Free tool
FAERS Monitor: Nitrogen, Nf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205839 or its brand name (Nitrogen, Nf, Nitrogen). Reports on generic versions are filed under their own applications.
Reports
111
Serious
94
85% of reports
Hospitalization
33
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malaise10
- off label use10
- drug interaction7
- accidental exposure to product6
- psoriasis6
- completed suicide5
- dyspnoea5
- haemodynamic instability5
- nausea5
- product leakage5
- ventricular fibrillation5
- weight decreased5
- death4
- dry gangrene4
- extremity necrosis4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 13 |
| 2018 | 15 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,048 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dry gangreneSignal | 4 | 1202.4 | 457.9 | 3,652 |
| extremity necrosisSignal | 4 | 435.5 | 166.2 | 1,324 |
| product leakageSignal | 5 | 169.0 | 71.7 | 675 |
| haemodynamic instabilitySignal | 5 | 124.4 | 52.8 | 495 |
| ventricular fibrillationSignal | 5 | 85.3 | 36.2 | 337 |
| completed suicideSignal | 5 | 11.4 | 4.8 | 38 |
| accidental exposure to productSignal | 6 | 11.0 | 5.1 | 45 |
| psoriasisSignal | 6 | 8.7 | 4.0 | 34 |
| drug interactionSignal | 7 | 8.4 | 4.1 | 39 |
| malaiseSignal | 10 | 4.3 | 2.4 | 23 |
| weight decreasedSignal | 5 | 3.4 | 1.4 | 6 |
| off label useSignal | 10 | 2.2 | 1.2 | 5 |
| dyspnoea | 5 | 1.7 | 0.7 | 1 |
| nausea | 5 | 1.2 | 0.5 | 0 |
| death | 4 | 0.9 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.